Publications - Companion Diagnostics
Jillian A. Moran, BA; Daniel L. Adams, BS; Martin J. Edelman, MD; Pablo Lopez, PhD; Jianzhong He, PhD; Yawei Qiao, PhD;
Ting Xu, PhD; Zhongxing Liao, PhD; Kirby P. Gardner, MBS; Cha-Mei Tang, ScD; and Steven H. Lin, MD, PhD2022 American Society of Clinical Oncology
Clinical Applications of Cancer-Associated Cells Present in the Blood of Cancer Patients.
Cha-Mei Tang and Daniel L. Adam.
Biomedicines 2022, 10, 587.
Blood-based biopsies – Clinical Utility beyond circulating tumor cells.
Tang CM, Zhu P, Li S, Makarova OV, Amstutz PT, Adams DL.
Cytometry Part A, first published: 19 October 2018. DOI: 10.1002/cyto.a.23573
Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang C-M, Lin SH,
Clinical Cancer Research, Published OnlineFirst August 16, 2017 DOI: 10.1158/1078-0432.CCR-17-0802
1st International Conference on Polyploid Giant Cancer Cells: Biology and Clinical Application 2024: PD-L1 Expression on Circulating Tumor Associated Macrophage Polyploids Predicts Patient Outcomes in Metastatic Breast Cancer
Immunology 2023 Poster: PD-L1 expression on circulating antigen presenting macrophages in blood predicts PFS & OS in an array of metastatic cancer types treated with PD-L1/PD-1 immunotherapies
AACR 2023 Poster: Micronuclei in circulating stromal cells correlates with PD-L1 expression and predicts progression in metastatic breast cancer
ASCO 2022 Poster: Monitoring PD-L1 Expression on Circulating Stromal Cells in Blood Predicts PFS and OS in Metastatic NSCLC Patients Treated with PD-L1/PD-1 Immunotherapy
ASCO 2021 Poster: Sequential Monitoring of PD-L1 on Circulating Stromal Cells in Blood Predicts PFS in NSCLC Patients Undergoing Immunotherapy after Definitive Chemoradiation